Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	4795	1330-43-4

Description:

Molecule	Description
Synonyms: sodium borate borax sodium tetraborate	see also sodium borate Molecular weight: 201.21 Formula: B4Na2O7 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 107.95 ALOGS: ROTB: None

Molecule

Description

Synonyms:

sodium borate
borax
sodium tetraborate

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Gastrointestinal toxicity	302.15	17.74	81	6863	9386	90612117
Pulmonary toxicity	277.30	17.74	79	6865	11452	90610051
Neoplasm malignant	211.13	17.74	84	6860	33796	90587707
Joint injury	203.59	17.74	81	6863	32583	90588920
Hepatotoxicity	202.72	17.74	89	6855	45753	90575750
Therapy non-responder	103.84	17.74	85	6859	136619	90484884
Joint stiffness	103.58	17.74	68	6876	77974	90543529
Musculoskeletal pain	98.79	17.74	91	6853	171160	90450343
Therapeutic product effect incomplete	89.21	17.74	91	6853	193805	90427698
C-reactive protein abnormal	81.90	17.74	72	6872	127357	90494146
Vaginal flatulence	70.61	17.74	29	6915	12609	90608894
Proctitis	65.34	17.74	29	6915	15230	90606273
Female genital tract fistula	60.97	17.74	29	6915	17839	90603664
Radiculopathy	60.00	17.74	29	6915	18476	90603027
Vaginal discharge	58.61	17.74	29	6915	19435	90602068
Pain in extremity	58.38	17.74	115	6829	450414	90171089
Musculoskeletal stiffness	56.94	17.74	90	6854	296442	90325061
Procedural pain	54.04	17.74	33	6911	33327	90588176
Colitis ulcerative	53.25	17.74	41	6903	60225	90561278
Chronic sinusitis	53.10	17.74	29	6915	23773	90597730
Paraesthesia oral	47.93	17.74	30	6914	31629	90589874
Oral candidiasis	44.83	17.74	30	6914	35425	90586078
Haematochezia	43.38	17.74	39	6905	70874	90550629
Macular degeneration	42.96	17.74	30	6914	37940	90583563
Frequent bowel movements	42.31	17.74	35	6909	56900	90564603
Treatment failure	41.01	17.74	79	6865	303849	90317654
Infection	37.03	17.74	84	6860	362010	90259493
Allergy to chemicals	29.38	17.74	11	6933	3743	90617760
Red blood cell sedimentation rate decreased	28.90	17.74	8	6936	1040	90620463
Synovial fluid analysis	28.58	17.74	10	6934	2808	90618695
Rectal haemorrhage	27.83	17.74	33	6911	82711	90538792
Synovial disorder	27.59	17.74	10	6934	3108	90618395
Colitis	27.08	17.74	30	6914	69912	90551591
Joint swelling	26.76	17.74	92	6852	503208	90118295
Antinuclear antibody positive	25.55	17.74	13	6931	9228	90612275
Tenosynovitis stenosans	25.28	17.74	10	6934	3943	90617560
Arthropathy	25	17.74	73	6871	366169	90255334
Hepatic enzyme decreased	24.98	17.74	7	6937	951	90620552
Eye irritation	23.40	17.74	20	6924	33958	90587545
Scleritis	22.62	17.74	10	6934	5198	90616305
Erythema	22.09	17.74	52	6892	229194	90392309
Condition aggravated	20.47	17.74	95	6849	595450	90026053
Arthralgia	20.36	17.74	115	6829	778407	89843096
Synovial cyst	19.99	17.74	12	6932	11740	90609763
Drug hypersensitivity	19.80	17.74	79	6865	463530	90157973
Cushingoid	18.68	17.74	11	6933	10384	90611119

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Periarthritis	32.47	24.28	8	1575	1372	42618380
Testicular haemorrhage	26.32	24.28	5	1578	252	42619500

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Gastrointestinal toxicity	182.92	18.65	55	7284	11093	110570867
Pulmonary toxicity	157.78	18.65	55	7284	17691	110564269
Neoplasm malignant	131.03	18.65	59	7280	37084	110544876
Joint injury	123.76	18.65	58	7281	39936	110542024
Hepatotoxicity	109.23	18.65	62	7277	63338	110518622
Joint stiffness	82.78	18.65	53	7286	67190	110514770
Vaginal flatulence	75.77	18.65	29	7310	12115	110569845
Female genital tract fistula	67.14	18.65	29	7310	16490	110565470
Proctitis	66.46	18.65	29	7310	16898	110565062
Vaginal discharge	64.89	18.65	29	7310	17879	110564081
Radiculopathy	62.76	18.65	29	7310	19307	110562653
Macular degeneration	62.65	18.65	30	7309	21629	110560331
Colitis ulcerative	62.32	18.65	47	7292	77316	110504644
Therapy non-responder	57.30	18.65	61	7278	157246	110424714
Procedural pain	56.47	18.65	33	7306	35532	110546428
Musculoskeletal pain	56.37	18.65	65	7274	182958	110399002
Chronic sinusitis	55.59	18.65	29	7310	25055	110556905
Therapeutic product effect incomplete	55.15	18.65	71	7268	223734	110358226
Frequent bowel movements	52.31	18.65	41	7298	71349	110510611
Paraesthesia oral	50.20	18.65	30	7309	33641	110548319
Haematochezia	42.40	18.65	45	7294	115479	110466481
C-reactive protein abnormal	41.49	18.65	47	7292	129648	110452312
Oral candidiasis	40.10	18.65	29	7310	44731	110537229
Pain in extremity	32.67	18.65	88	7251	487030	110094930
Allergy to chemicals	32.23	18.65	11	7328	3314	110578646
Synovial fluid analysis	30.48	18.65	10	7329	2671	110579289
Musculoskeletal stiffness	30.24	18.65	61	7278	279761	110302199
Rectal haemorrhage	29.45	18.65	38	7301	119795	110462165
Synovial disorder	29.35	18.65	10	7329	2997	110578963
Red blood cell sedimentation rate decreased	28.12	18.65	8	7331	1326	110580634
Infection	27.94	18.65	69	7270	362131	110219829
Tenosynovitis stenosans	27.58	18.65	10	7329	3593	110578367
Therapeutic reaction time decreased	27.27	18.65	11	7328	5268	110576692
Hepatic enzyme decreased	25.67	18.65	7	7332	995	110580965
Synovial cyst	24.71	18.65	13	7326	11417	110570543
Colitis	24.44	18.65	32	7307	102291	110479669
Antinuclear antibody positive	24.40	18.65	12	7327	9156	110572804
Abdominal pain	24.29	18.65	82	7257	512907	110069053
Erythema	24.05	18.65	57	7282	291390	110290570
Treatment failure	23.72	18.65	55	7284	277179	110304781
Scleritis	23.62	18.65	10	7329	5410	110576550
Testicular haemorrhage	23.50	18.65	5	7334	248	110581712
Constipation	22.33	18.65	63	7276	357723	110224237
Dyspepsia	22.27	18.65	43	7296	190922	110391038
Joint swelling	20.25	18.65	70	7269	442775	110139185
Quality of life decreased	19.51	18.65	12	7327	14157	110567803
Cushingoid	18.93	18.65	11	7328	11701	110570259
Rheumatoid arthritis	18.92	18.65	53	7286	299560	110282400

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	S01AX07	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Other antiinfectives
CHEBI has role	CHEBI:50267	protective agent
CHEBI has role	CHEBI:66981	ophthalmology drug

Related Drugs by ATC class:

S01AX Other antiinfectives 13 drugs

bibrocathol cethexonium chlorhexidine dibrompropamidine hexamidine lotilaner nitrofurazone picloxydine polihexanide povidone-iodine propamidine resorcinol show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
91MBZ8H3QO	UNII
D03243	KEGG_DRUG
4024916	VUID
N0000147505	NUI
4019309	VANDF
4024916	VANDF
C0074727	UMLSCUI
CHEBI:38909	CHEBI
CHEMBL3833375	ChEMBL_ID
16211214	PUBCHEM_CID
DB14505	DRUGBANK_ID
CHEMBL2097011	ChEMBL_ID
CHEMBL1076681	ChEMBL_ID
C010634	MESH_SUPPLEMENTAL_RECORD_UI
C018851	MESH_SUPPLEMENTAL_RECORD_UI
36680	RXNORM
5210	MMSL
5475	MMSL
NOCODE	MMSL
001980	NDDF
011732	NDDF
50306007	SNOMEDCT_US
1303-96-4	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Calcemin Advance	HUMAN OTC DRUG LABEL	5	0280-0272	TABLET, FILM COATED	2.45 mg	ORAL	Export only	1 sections
MA YING LONG HEMORRHOIDAL	HUMAN OTC DRUG LABEL	7	69396-006	OINTMENT	0.20 g	TOPICAL	unapproved drug other	11 sections
Miel Rosada	HUMAN OTC DRUG LABEL	2	70242-127	SOLUTION	0.10 mg	TOPICAL	OTC Monograph Drug	8 sections
Borax	HUMAN OTC DRUG LABEL	1	79718-1023	LIQUID	30 [hp_C]	ORAL	unapproved homeopathic	7 sections
Borax	HUMAN OTC DRUG LABEL	1	79718-1164	LIQUID	200 [hp_C]	ORAL	unapproved homeopathic	8 sections

Ask DrugCentral

sodium borate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: